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aTo be, or not to be – that is the question: Act III
scene I, Hamlet. William Shakespeare
Upon the occasion of the 37th annual meeting of the
New England Society for Vascular Surgery, we are re-
minded that ours is the oldest regional vascular society. The
annual meetings have been the forum for presentation of
important clinical findings and operative techniques by
luminaries in our field. We have had presentations on
preoperative preparation, postoperative care, basic science,
and the requisite presidential address. Today, our plenary
sessions are replete with papers on endovascular surgery
and analyses of databases, which represents a dramatic
change from 10 years ago.
I am grateful to the society for the privilege of this
office. One of the prerogatives of a presidential address is
that one is permitted if not expected to make some ac-
knowledgments. Allow me to begin by expressing my ap-
preciation to those who have made important contribu-
tions to my professional development. It would be
appropriate to start with my parents, who were important
role models for me. I am a third-generation physician. My
father emigrated to this country from Denmark as a Ful-
bright scholar. He joined the staff at the University of
Rochester School ofMedicine and retired from the Depart-
ment of Anesthesiology 30 years later. I would also like to
mention my companion, Katarina Sawtelle, MD, who has
always been much more than supportive, and my daughter,
Anna. There is a lot of negativity in our world of surgery
today, but it would not disappoint me if my daughter were
to choose medicine as her profession.
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doi:10.1016/j.jvs.2010.11.091I attended the University of Rochester School of Med-
cine, and within the walls of Strong Memorial Hospital, I
as fortunate enough to watch and learn from Charles Rob
nd James DeWeese. During my general surgery residency
t what was then called the New England Deaconess
ospital-Harvard 5th Surgical Service, I learned attention
o detail and the importance of meticulous care. I remained
n Boston for my fellowship at the Tufts-New England
edical Center under the tutelage of Drs Callow,
’Donnell, Mackey, and Deterling, who were, respec-
ively, the 7th, 24th, 37th, and 2nd presidents of this
ociety. If success didn’t follow this training, it would be
lear where the fault lies. As I look back, I realize the
mportance of the year doing laboratory research under the
irection of Dr Callow. During the year spent in his labo-
atory, I learned the scientific basis of vascular surgery. My
nowledge of the literature expanded immensely and
ormed the foundation of the rest of my career. For those
ho question the value of laboratory research, I would
ubmit that the intangibles are immeasurable. I would
lso like to express my appreciation to Dr Carl Breden-
erg, former Chairman of the Department of Surgery,
aine Medical Center, and the 28th president of our
ociety, whose support and guidance has been invalu-
ble.
Let me begin with an analogy. Imagine yourself stand-
ng on a slope in the Rocky Mountains at an altitude of
2,000 feet. Last night, 1 foot of dry fluffy Rocky Moun-
ain powder fell, the sky is blue, and the snow is untracked.
ou have just hiked 1 mile along a razor’s edge, carrying
our skis on your shoulder. You are looking over the
recipice of the famed Highland Bowl in Aspen, Colorado
Fig 1). You step into the bindings of high-performance
alomon skis (Salomon SAS, Annecy, France) and adjust
he buckles on Lange competition boots (Skis Dynastar
AS, Sallanches, France). The slope approaches 40 degrees,
nd after a rapid descent with a few quick turns, you are
tanding at the bottom, breathless and looking back at the
ountain. In such a situation, it is not difficult to define the
igh quality of the experience. But what defined the quality
the structure; the mountain, the snow, or the skis? The
rocess; the performance or the sensation?Or the outcome;
successful run, the tracks in the snow, or the memories
hat remain?
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March 2011846 Eldrup-JorgensenOf course, this paper is not about skiing but rather
about quality in health care and specifically in vascular
surgery. I will try to give a better understanding of quality
in medicine, how we measure it, and some of the contro-
versies in quality assessment. I will sharemy experience with
our regional vascular database and how we use it. Lastly, I
would like to discuss quality improvement using the story
of beta blockers as an example.
Over the past 20 years, quality has become the mantra
and the obsession of our profession. Yet quality is difficult
to define, difficult to measure, and difficult to achieve. The
focus on quality has been highlighted by the Institute of
Medicine (IOM) report “Crossing the Quality Chasm,”
which cemented the importance of continuous quality im-
provement in our profession and brought it to the forefront
of the attention of the general public.1
The IOM defined health care quality as “the degree to
whichhealth services for individuals andpopulations increased
the likelihood of desired health outcomes and are consistent
with current professional knowledge.” This seems to be a
rather complicated way of saying not too many patients had a
stroke following carotid endarterectomy!
QUALITY ASSESSMENT
Although quality seems easier to detect than define,
Donabedian, in his classic paper, described a systematic
method to quality assessment.2 He defined three ap-
proaches to measuring quality: structure, process, and out-
comes.3
Structural measures include physical or organizational
characteristics, such as equipment, technology, patient vol-
ume, nursing staff-to-patient ratios, speciality training, and
accreditation. Commonly used examples are surgical vol-
ume, board certification, computerized physician order
entry, and an intensive care unit staffed only by critical care-
trained physicians. The Leapfrog Group has endorsed
structural measures recommending volume standards for
selected operations such as carotid endarterectomy, ab-
Fig 1. Highland Bowl, Aspen, Colorado.dominal aortic aneurysm repair, coronary artery bypass wrafting, and surgery for pancreatic cancer and esophageal
ancer.4,5 A number of studies have shown a direct relation-
hip between surgical volume and outcomes.5-9 However,
he volume outcome relationship is controversial and has
een vigorously debated in the literature.10-18 The advan-
ages of structural components are that most are readily
dentifiable and easily measurable, such as surgical volume
r board certification. The disadvantage of structural ele-
ents is that they may not be important and may be
ifficult to implement. For example, does a hospital stop
oing an operation due to low volume or should it try to
ncrease its volume? Can every hospital recruit critical care
rained specialists to staff its intensive care unit?
Donabedian’s second approach to quality assessment is
rocess.2 Process measures describe the care the patient
eceives and would include vaccinations, screening mam-
ography, and care for acute myocardial infarction (MI);
e, administration of aspirin, beta blockers, and statins.
urgical process measures are deep vein thrombosis pro-
hylaxis, use of antibiotic-impregnated central venous pres-
ure lines, and appropriate use of antibiotic wound prophy-
axis. Many of these have been incorporated into the
urgical Care Improvement Project (SCIP) protocol. In
ascular surgery, process measures include use of patch
uring carotid endarterectomy and perioperative beta
lockers and aspirin. The advantage of process measures is
hat they are part of patient care and can be implemented by
he treating physician, but this is also one of the disadvan-
ages – it requires the clinician to modify his or her current
anagement. One of the other disadvantages of many
rocess improvement measures is the degree of impact.
uch of the literature on process improvement relates to
edical management of surgical patients, yet many postop-
rative adverse events are related to the technical perfor-
ance of the operation itself and not to the perioperative
are.
Finally, Donabedian proposed that quality could be
ssessed by measuring the outcome, whether the patient
urvived and whether complications developed.2 Donabe-
ian described it well, “Outcomes, by and large, remain the
ltimate validation of the effectiveness and quality of health
are.”3 The importance of outcomes is intuitive and does
ot need explanation. However, it must be kept in mind
hat outcomes cannot distinguish efficacy from effective-
ess. Good outcomes may result despite bad care or more
ommonly from an unindicated procedure. Outcomes are
ependent on co-morbidities and need to be risk-adjusted.
ther important limitations of using outcomes analysis to
ssess quality are determining clinically relevant variables
nd achieving adequate sample size.
ATABASES
Surgeons are interested in procedure-specific outcomes
graft patency, stroke rate, and incidence of myocardial
omplications. Surgeons are particularly interested in their
wn outcomes and comparison to their peers. Unfortu-
ately, important clinical variables such as graft patency or
ound infection are not readily accessible or measurable
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Volume 53, Number 3 Eldrup-Jorgensen 847without in-depth chart review. Clinical outcomes are usu-
ally not present in administrative or billing databases but
require the granularity of clinical databases.
Outcome databases were initially developed in surgical
divisions, notably transplant, trauma, cardiac, and vascular
surgery. Clinical outcomes assessment has been further
popularized by national and regional databases such as the
Northern New England Cardiovascular Disease Study
Group (NNECDSG), National Surgical Quality Improve-
ment Program (NSQIP), and Vascular Study Group of
New England (VSGNE).19-21 NSQIP is a large and widely
reported nationwide clinical database.15,20,22-26 NSQIP
investigators have been collecting data and reporting risk-
adjusted outcomes for 20 years. Khuri et al have looked at
mortality and postoperative complications based on over
70 demographic, clinical, and outcome variables.20,22
NSQIP investigators have ranked their hospitals according
to mortality rates.
These mortality results have been reported to individ-
ual institutions for internal review. Over time, NSQIP has
demonstrated a system-wide 27% decrease in mortality and
a 45% decrease in morbidity.26 The NSQIP data analysis of
unadjusted mortality rates identified high and low outliers
(significantly higher or lower mortality rates based on ob-
served-to-expected [O/E] ratios).22 However, when the
data were further analyzed using risk-adjusted O/E ratios,
some of the ratios were dramatically reordered. NSQIP
found that 25 of 39 or 64% of these outliers were found to
have been inaccurately identified, emphasizing the impor-
tance of risk adjustment.
NSQIP also reviewed the efficacy of analyzing clinical
outcomes from administrative databases compared with clin-
ical databases for proper risk adjustment.24 They found that
mortality ranking could not be accurately based on informa-
tion derived from administrative databases but required the
specific clinical information provided by using a clinical data-
base.
Hospital outcomes are readily accessible to hospital
administrators, third-party payers, and patients. An Inter-
net search will readily provide rankings and evaluations of
hospitals based on outcomes obtained from administrative
and billing databases (usually crude mortality rates). A
desire to better understand their own outcomes has led
many surgeons to participate in clinical databases. This has
allowed practitioners to review their results and confirm the
validity of administrative data.
VSGNE
NSQIP and NNECDSG have shown the value of a
risk-adjusted database and quality improvement initia-
tives.15,19 Based on the success of these prior initiatives, a
group of vascular surgeons from Maine, New Hampshire,
and Vermont met in 2002 to discuss the formation of a
regional study group with the purpose of outcomes evalu-
ation and quality improvement. Under the leadership of Dr
Jack Cronenwett from Dartmouth-Hitchcock Medical
Center, with collaboration from Dr Carl Bredenberg,
MaineMedical Center, and Dr David Pilcher, University of permont, and others, we formed the Vascular Study Group
f Northern New England (now the VSGNE).21 At the
ime of inception, there were nine centers and 42 surgeons
n the study group. At present, there are 22 centers and 117
urgeons in the region who have committed to enter all
atients who undergo an index procedure – carotid endar-
erectomy or stenting, open or endovascular abdominal
ortic aneurysm repair, and lower extremity revascularization.
he database contains over 14,000 patients who have under-
one one of the above procedures with 1-year follow-up on
ver 85% of the patients. VSGNE currently has members
rom Massachusetts, Rhode Island, and Connecticut, and
ffiliate members from the Carolinas, Texas, Florida, Cali-
ornia, and Ontario, Canada.
The VSGNE meets biannually to share outcomes and
iscuss quality improvement. Each center receives a graphic
epresentation of its own outcomes on such parameters as
troke rate, graft patency, MI, death, blood loss, aspirin
sage, beta blocker usage, and length of stay compared
ith regional norms. Individual results and center results
re reported to each surgeon. Blinded results from all other
urgeons and centers are reported to all participants to
llow benchmarking. The biannual meetings have pro-
oted collegiality and collaboration, which have been crit-
cal to the success of this project.
At Maine Medical Center, we have used the VSGNE
atabase as the basis for our own divisional registry for
utcomes assessment and quality assurance. We regularly
eview procedure-specific outcomes – patency rates, wound
omplications, stroke, etc (Fig 2). Again, each surgeon is
iven his own results as well as blinded reports of col-
eagues. Reports are also generated for other important
ostoperative outcomes, such as MI, death, blood loss,
eturn to operating room, and length of stay. This dataset
llows closer inspection of processes of care such as periop-
rative aspirin, beta blocker or statin usage, vein versus
ynthetic graft, or open versus endovascular approach. The
eports can be tailored depending on the interest. If an
ntoward event or cluster of events occurs, such as infec-
ion or wound complications, it allows ready identification
nd further evaluation. The database provides an easy
echanism for tracking SCIP criteria. It also allows us to
xamine cost per procedure in detail.
ERIOPERATIVE BETA BLOCKERS
At the inception of VSGNE, a number of process
mprovement initiatives were undertaken, including use of
arotid patching, and perioperative use of aspirin, beta
lockers, and statins.27 At the time, there were class I and
Ia recommendations for the use of perioperative beta
lockers for patients undergoing major vascular opera-
ions.28 Many prominent health policy groups endorsed
he use of perioperative beta blockers, including the Leap-
rog Group for Patient Safety, National Quality Forum,
urgical Care Improvement Project, and the Agency for
ealthcare Research and Quality.29-32
VSGNE supported an initiative promoting the use of
erioperative beta blockers.27 A beta blocker committee
T
2
a
w
p
s
b
c
t
card
JOURNAL OF VASCULAR SURGERY
March 2011848 Eldrup-Jorgensenwas formed and provided informational sessions at VSGNE
meetings. The committee reviewed the current literature,
developed a standardized dosage regimen, and made rec-
ommendations for implementation. The committee also
created ancillary support material, including a letter to be
sent to primary care providers explaining the rationale for
perioperative beta blocker use, an information sheet for
patients, and preprinted prescription blanks. The goal was
to facilitate the implementation of a perioperative beta
blocker protocol for all providers at each institution such
Fig 2. Institutional reportthat 90% of patients were on perioperative beta blockers. the recommended standardized regimen was metoprolol
5mg orally twice a day to begin 2 weeks prior to operation
nd to be continued for 2 weeks following operation.
When the initiative was begun in 2003, 54% of patients
ere on chronic beta blocker therapy. Of the preoperative
atients who were not on beta blockers when seen in the
urgeon’s office, 44% of patients were started on beta
lockers perioperatively. Combining the patients on
hronic and those started on perioperative beta blockers,
here were a total of 68% of patients on beta blockers at the
for lower extremity bypass.ime of operation in 2003. By the end of 2008, 61% of
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Volume 53, Number 3 Eldrup-Jorgensen 849patients arriving at the surgeon’s office were on chronic
beta blockers, and beta blockers were started on 78% of
patients not on them, for a total (Fig 3) of 88% of patients
on beta blockers at the time of operation. In brief, the
percentage of patients on beta blockers went from 68% to
88% over a 5 year period of time, mostly due to an increase
in the perioperative initiation of beta blockers that went
from 44% to 78%.27 This process improvement initiative
appeared to be successful as perioperative beta blocker
utilization progressively increased in our region over time
for all surgeons (Fig 4,A) and all centers (Fig 4, B). Almost
all patients who did not have a contraindication were on
chronic or perioperative beta blockers. For most of the last
3 years, the VSGNEbeta blocker utilization rate has been at
90%. However, despite the increased use of beta blockers,
there was no discernible effect on postoperative MI rate or
postoperative mortality. At the beginning of the project,
the postoperative MI rate was 5.2%, and 5 years later in
2008, the postoperative MI rate was 5.5% (Fig 5). The
one-year mortality was 12.8% in 2003 and 12.1% in 2008
(ns; Fig 5). Given this extensive effort and obvious success
at process improvement, the lack of clinical impact was
cause for further evaluation.
Beta blockers block the action of endogenous cat-
echolamines on beta-adrenergic receptors. There are three
known receptor types: beta 1, 2, and 3. Beta-1 adrenergic
receptors are located in the heart and kidneys; beta-2
receptors are in the pancreas, liver, fat, uterus, vascular
smooth muscle, and skeletal muscle; and beta-3 receptors
are found in the fat. Non-selective agents, such as propran-
olol and labetolol, block all three receptors. Beta-1 selective
agents, metoprolol and bisoprolol, act only on the heart.
Beta blockers act by decreasing heart rate and contractility,
thereby balancing myocardial supply and demand and re-
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Fig 3. Percentage of patients (VSGNE) stduce cardiac events.33 Beta blockers are also thought to utabilize coronary plaque, inhibit renin release, and increase
he threshold for tachyarrhythmias.34,35
When beta blockers were introduced into clinical prac-
ice, they were contraindicated in patients undergoing op-
rations, as beta blockers were felt to blunt the compensa-
ory sympatho-mimetic response to stress. Eventually, this
oncept proved false, and beta blockers were increasingly
sed in the 1990s for cardiac syndromes, including conges-
ive heart failure. After time, it was deemed safe to continue
eta blockers for patients undergoing operation. As beta
lockers became increasingly used for the management of
cute myocardial syndromes, they were found to be bene-
cial in patients with coronary artery disease undergoing
ajor operations. One of the seminal studies showing a
ecrease in postoperative cardiovascular events was re-
orted by Mangano in the New England Journal of
edicine in 1996.36 Two hundred patients at risk for
oronary artery disease undergoing noncardiac surgery
ere randomized to a beta blocker or control. They
howed that a single dose of atenolol preoperatively,
hich was continued for 1 week, reduced cardiac and
ll-cause mortality as well as nonfatal cardiac events at 6
onths and 2 years.
Another randomized clinical trial by Poldermans in
999, the Dutch Echocardiographic Cardiac Risk Evalua-
ion Applying Stress Echocardiography (DECREASE)
rial, showed decreased MI and cardiovascular mortality in
atients on perioperative beta blockers.37 In this trial of
12 high-risk patients (patients had both clinical risk fac-
ors and a positive dobutamine echocardiogram), the
roup randomized to bisoprolol had dramatic reductions in
erioperative cardiac death and nonfatal MI. The results
ere so compelling that a safety committee ordered early
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59% 64% 61%
33%
28%
31%
2006 2007 2008
ar
A BLOCKERS
 BLOCKERS
on perioperative beta blockers over time.er
5
Ye
IC BET
 BETAnblinding and cessation of the study.
f
r
i
I
i
o
T
e
f
d
o
P
3
(VSG
JOURNAL OF VASCULAR SURGERY
March 2011850 Eldrup-JorgensenThese early studies were followed by a multitude of
clinical studies and randomized clinical trials.38-49 Most of
the early reports showed a beneficial effect of perioperative
beta blockers, but then some trials began reporting absence
of effect and even adverse events.
The PeriOperative Beta-BLockadE for patients under-
going infrarenal vascular surgery (POBBLE) published in
the Journal of Vascular Surgery in 2005 looked at 103
patients randomized to atenolol or control.39 The patients
on perioperative beta blockers did not show any reduction
in postoperative cardiovascular events.
Nor was there a positive impact in the Metoprolol after
Vascular Surgery (MaVS) trial published in the American
Heart Journal in 2008. Yang et al randomized 496 patients
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Because of the ongoing controversy, a large random-
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Volume 53, Number 3 Eldrup-Jorgensen 851men that was used. Metoprolol, 100 mg, was initiated 2 to
4 hours prior to operation, which may have contributed to
intraoperative bradycardia and hypotension. Interestingly,
sepsis was a common cause of death in this trial, and there
is speculation that sepsis may have been related to the
hypotension. One of the conclusions of this large random-
ized study was “the importance and need for large random-
ized trials.”
The role of beta blockers in perioperative care has
spawned hundreds of articles, many editorials, over nine
randomized clinical trials,36,37,39,40,42-49 and seven meta-
analyses.50-56 In non-cardiac operations, which include
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RCRI, Relative cardiac risk index; RCT, randomized clinical trial.
Extracted from Brooke.67vascular, general, and orthopedic surgery, there appears to ae a benefit with decreased postoperative cardiac events,
ut there is increasing recognition of lack of effect and
ppearance of adverse events (Table I). It should be noted
hat the most common reported adverse events are brady-
ardia and hypotension. Prior to POISE, there had not
een reports of increased mortality or stroke in the beta
locker studies. In studies of vascular surgery patients, most
how decreased cardiovascular events and mortality, al-
hough there have been some reports with lack of effect
Table II).
The variable effect of beta blockers on perioperative
utcomes can be explained, at least in part, by a defining
lity Over Time
 2003-2008
Oct-
December 
2008tality
12.1% p=0.782
-
r
April-
June
06
July-
Sept
06
Oct-
Dec
06
Jan-
Mar
07
April-
June
07
July-
Sept
07
Oct-
Dec
07
Jan-
Mar
08
Apr-
Jun
08
July-
Sept
08
Oct-
Dec
08
y (dots), and postoperative MI rate (squares) over time in
t al27).
ients
esults Adverse outcomes
ardiac
a
No
ortality Increase bradycardia
ardiac
a
Increase bradycardia
ortality for
or 3
Increase mortality for RCRI 0
Increase bradycardia and hypotension
I and
ed CV events
Increase bradycardia and hypotension,
increase mortality and cerebrovascular
accidentrta
GNE
Mor
Oct-
Dec
05
Jan
Ma
06
rtality pat
R
ease c
hemi
ease m
year)
ease c
hemi
ease m
RI 2
ffect
ease M
mbinrticle by Lindenauer et al in the New England Journal of
c
a
(
o
h
p
i
A
c
m
e
m
c
w
t
i
c
t
M
t
a
t
a
i
i
P
c
g
i
JOURNAL OF VASCULAR SURGERY
March 2011852 Eldrup-JorgensenMedicine in 2005.57 They analyzed beta blockers by retro-
spectively reviewing an administrative database, albeit one
that was focused on quality and use of care. The analysis
reviewed 782,969 patients in 329 hospitals; 663,635 pa-
tients did not have any contraindication to beta blockers,
and of those, 122,338 received beta blocker within 2 days
of their admission to the hospital, and hence were felt to be
on perioperative beta blockers. Lindenauer demonstrated
reduced in-hospital death in the patients receiving periop-
erative beta blockers. The benefits were shown to be de-
pendent on risk. The most widely used risk assessment
model is the revised cardiac risk index (RCRI).58 The RCRI
is a 6 point scale consisting of six risk factors, including
high-risk surgery, ischemic heart disease, congestive heart
failure, cerebrovascular disease, insulin-dependent diabetes
mellitus, and renal failure (creatinine 2). Using the
RCRI, the incidence of postoperative complications is re-
lated to the number of risk factors. The degree of risk in
vascular patients has been further refined with an analysis by
Bertges et al from the VSGNE.59
Lindenauer et al showed that in moderate- to high-risk
patients (RCRI 2), beta blockers were clearly benefi-
cial.57 In low-risk patients (RCRI 0,1), there was no
benefit and possible harm. They found reduced in-hospital
mortality in moderate- to high-risk patients, but not in
low-risk patients and hence, the impact of beta blockers
appears to be dependent on the patient’s level of risk.
This analysis may explain the lack of effect on postop-
erative MI and mortality in selected trials. The lack of
impact on outcomes in the VSGNE beta blocker process
improvement project may have been due to a low number
Table II. Beta blocker studies involving vascular surgery p
Author Study
Raby42 1999 RCT
Poldermans/DECREASE37 1999 RCT
Boersma38 2001 Cohort
Kertai41 2004 Cohort
Brady/POBBLE39 2005 RCT
Yang/MaVS48 2006 RCT
Brooke69 2008 Cohort
Suttner44 2009 RCT
MI, Myocardial infarction; RCT, randomized clinical trial.
Extracted from Brooke.67
Table III. Meta-analyses of beta blocker studies showing
Author Studies Pts
Cardi
ischem
McGory52 2005 6 632 0.47
Devereaux51 2005 22 2437 NA
Schouten53 2006 15 1077 0.35
Wiesbauer55 2007 27 2057 0.38
Bangalore50 2008 33 12,306 0.36
Talati54 2009 6 10,183 NA
Stevens56 2009 6 866 0.46of patients at risk. There was a high incidence of patients on ghronic beta blockers (54% to 61% from 2003 to 2008) and
relatively low number of moderate- to high-risk patients
RCRI 1) not on chronic beta blockers.27 By 2008, 73%
f high-risk patients were on chronic beta blockers, and
ence only 27% would have been available to benefit from
erioperative beta blocker treatment.
There are seven meta-analyses evaluating 6 to 33 stud-
es, including 632 to 12,306 patients50-56 (Table III).
lmost all of the meta-analyses show a decrease in non-fatal
ardiac events in patients on beta blockers. Postoperative
ortality has been decreased in almost all of the studies,
specially the earlier ones, but the effect on mortality is
ostly dependent upon whether the meta-analysis in-
luded POISE.49 POISEhas contributed over 8000 patients,
hich make up over three-quarters of the patient volume in
he respectivemeta-analyses. This volume has an overwhelm-
ng impact on the interpretation of the meta-analysis. The
ritics of POISE say the dose was too large and poorly
imed, having an aberrant effect on postoperative mortality.
ost experts currently recommend a “run in” period and
itration to heart rate.60-63 Excluding POISE, beta blockers
re shown to decrease postoperative cardiac mortality. For
hose who believe that results from POISE are applicable to
ll patients, the decrease in cardiac mortality is offset by an
ncrease in non-cardiac mortality, and beta blockers do not
mpact postoperative death. However, even including
OISE, beta blockers have been shown to reduce non-fatal
ardiac events and mortality in high-risk patients.
The literature on perioperative beta blockers is hetero-
eneous, complex, and may seem contradictory. The stud-
es include non-cardiac surgery, including vascular surgery,
ts
ts Results
26 Decrease 30 day cardiac ischemia
12 Decrease 30 day MI and cardiovascular mortality
92 Decrease 30 day MI or mortality
70 Decrease 30 day MI or mortality
97 No effect
96 No effect
70 Decrease mortality
50 Decrease cardiac ischemia
ve risk of postoperative events
Nonfatal myocardial
infarction
Cardiovascular
death
All
death
0.14 0.25 0.52
0.38 0.4 0.56
0.44 0.55 0.79
0.59 NA 0.78
0.65 1.15 1.20
0.74 NA 1.21
0.19 0.25 NAatien
P
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population selected. This leads us to ask the question,
“Should we use perioperative beta blockers?” or, as Hamlet
has been quoted as saying while wandering the halls of
Elsinore Castle in Denmark, “To be or not to be?”64
CURRENT RECOMMENDATIONS
The data on beta blockers have been extensively re-
viewed by a number of societies. A consensus paper from
the European Society of Cardiology and the European
Society of Anesthesia drew the following conclusions:60
1. Beta blocker usage results in a significant reduction in
perioperative ischemia, MI, and cardiac mortality.
2. The risk reduction is more marked in high-risk patients.
3. Beta blockers do not decrease the risk in low-risk pa-
tients.
4. Ischemia and troponin are reduced and long-term out-
come improved in patients with a lower heart rate.
The consensus statement from the European societies rec-
ommends that beta blockers should be titrated starting 30
days preoperatively and at least 7 days preoperatively.60
They recommend using a beta-1 selective agent, either
bisoprolol or metoprolol.
The American College of Cardiology and American
Heart Association (ACC/AHA) consensus guidelines of
2009 state there is a class I recommendation to continue
beta blockers in patients who are currently taking them.61
There is a class IIa recommendation to start titrated
beta blockers in patients with coronary artery disease or
intermediate- to high-risk patients. The ACC/AHA guide-
lines state there is a class IIb recommendation for beta
blockers in intermediate- to low-risk patients, and the
usefulness is uncertain.
To summarize, in clinical practice, vascular surgeons
should continue beta blockers for patients already on them.
Beta blockers should be started preoperatively in selected
patients undergoing vascular surgery (especially high-risk
patients). When using beta blockers, one should try to start
at least 1 week preoperatively, use a selective agent, and
titrate the dose.
REGIONAL CLINICAL TRIALS
The irony of the beta blocker story is that there have
been hundreds of studies, over nine randomized clinical
trials,36,37,39,40,42-49 seven meta-analyses,50-56 and many
editorial opinions and recommendations,60-63,65-71 yet we
still lack clarity. What can we do as practicing vascular
surgeons and as members of the New England Society for
Vascular Surgery to help answer these and other important
clinical questions? I would like to propose for consideration
one approach – to do regional clinical trials. Let me begin
by stating that this is not a new or original idea. In his 1998
NESVS presidential address, Jack Cronenwett put forth the
concept of cooperative clinical research trials and even then
stated that it was not a novel idea.72 He proposed that our
society “establish a Clinical Trials Committee to receive
and review proposals for such studies from our members, to oelect studies for sponsorship, to invite other members to
articipate, and to monitor the implementation and perfor-
ance of the resulting trials.” There have been a number of
egional, cooperative clinical trials, notably from the Joint
ascular Research Group in England.73,74 This concept has
een raised at our and other regional societies, but it has
een difficult to bring to fruition.
Focused clinical research studies could look at straightfor-
ard, pertinent, clinical questions in a systematic fashion. A
linical trials group could readily increase the number of
atients in a study without the bureaucracy or major expense
f a funded trial. Potential questions to address include open
ersus endovascular repair of popliteal aneurysms, choice of
lternative conduits for tibial bypass, discontinuation of Plavix
reoperatively, or use of Protamine. The issue with any inves-
igator trying to address these questions in a single center
tudy is recruiting enough patients to provide meaningful
tatistical analysis. With a regional cooperative effort, investi-
ators can readily increase the number of patients and hence,
he power of their data analysis.
VSGNE has shown that a regional cooperative process
mprovement measure can be successful. A NESVS Clinical
rials Committee can provide a collaborative atmosphere
ith infrastructure, oversight, and guidance. It would pro-
ote further cooperation and collegiality throughout our
egion. It would allow smaller centers and community
ractice surgeons to participate in meaningful scientific
nvestigations. Such an effort is not meant to replace the
SGNE, analysis of national databases, or single-center
tudies. Other specialities (eg, cardiology and oncology)
ave been successful at performing cooperative random-
zed clinical trials. A NESVS Clinical Trials committee
ould allow our speciality to evaluate new technologies
uch as atherectomy, balloon cryoplasty, and tibial angio-
lasty using evidence-based medicine. It seems logical that
ndustry would be interested in supporting such endeavors.
here is an opportunity for NESVS to address clinical
uestions and support investigative efforts.
At my request, the executive council of the NESVS has
ppointed an ad hoc Clinical Trials Committee. The commit-
ee is in the process of preparing a report on how to move
orward.We hope this will allow us as vascular surgeons and as
embers of NESVS to address important clinical issues. De-
ermining the right thing to do (or addressing processes of
are) is one of the steps towards quality.
ONCLUSIONS
In conclusion, surgeons and society expect high qual-
ty. In order to measure quality reliably and meaningfully,
any surgeons have chosen to participate in clinical data-
ases. The Vascular Study Group of New England was
ormed . . . to improve care . . . and to improve quality . . . .
VSGNE has allowed us to evaluate quality in our region
nd at my own institution. VSGNE undertook a quality
mprovement initiative by addressing a process measure,
erioperative beta blocker usage. Despite a successful pro-
ess improvement initiative, there was no detectable impact
n outcomes. The literature on beta blockers has some
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tive in high-risk patients and may be of benefit in most
vascular surgery patients. Further refinement of our beta
blocker initiative may help us be more successful in future
quality-improvement efforts.
There are many other questions in vascular surgery that
need to be addressed in addition to beta blockers – the role
of statins, open versus endovascular approach to TASCCor
D lesions, and perioperative glycemic control, to name just
a few. These issues cannot be adequately addressed in
single-center studies, yet the expense and logistics of large
randomized clinical trials are prohibitive for most investi-
gators. NESVS has formed an ad hoc Clinical Trials Com-
mittee to facilitate and support regional clinical trials. We
hope such studies will help us address clinical questions and
improve the quality of our care.
I would like to gratefully acknowledge the valuable assis-
tance of Jill Knutson, RN, in the preparation of this article.
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